Fendiline inhibits K-Ras plasma membrane localization and blocks K-Ras signal transmission

Molecular and Cellular Biology

Volumn 33, Issue 2, 2013, Pages 237-251

  van der Hoeven, Dharini ^a,b   Cho, Kwang jin ^a   Ma, Xiaoping ^a   Chigurupati, Sravanthi ^a   Parton, Robert G ^c   Hancock, John F ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS DENTAL BRANCH AT HOUSTON   (United States)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CALCIUM CHANNEL L TYPE; FENDILINE; K RAS PROTEIN; PROTEIN KINASE C; RAF PROTEIN;

ANIMAL CELL; ARTICLE; CALCIUM CELL LEVEL; CELL FRACTIONATION; CELL GROWTH; CELL MEMBRANE; CELL PROLIFERATION; CELL TRANSFORMATION; CELL VIABILITY; CELLULAR DISTRIBUTION; COLON CANCER; CONTROLLED STUDY; CYTOSOL; CYTOTOXICITY; DRUG STRUCTURE; ENDOMETRIUM CANCER; ENDOPLASMIC RETICULUM; ENDOSOME; ENZYME INHIBITION; GOLGI COMPLEX; IC 50; LUNG CANCER; MEMBRANE DEPOLARIZATION; NONHUMAN; ONCOGENE H RAS; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; STATIC ELECTRICITY;

EID: 84871909237     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.00884-12     Document Type: Article

References (78)

1. Bos JL. 1989. ras oncogenes in human cancer: a review. Cancer Res. 49:4682-4689.
2. Downward J. 2003. Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer. 3:11-22.
3. Prior IA, Lewis PD, Mattos C. 2012. A comprehensive survey of ras mutations in cancer. Cancer Res. 72:2457-2467.
4. Corcoran RB, Settleman J, Engelman JA. 2011. Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers. Oncotarget 2:336 -346.
5. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB. 2010. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363:809-819.
6. Greger JG, Eastman SD, Zhang V, Bleam MR, Hughes AM, Smitheman KN, Dickerson SH, Laquerre SG, Liu L, Gilmer TM. 2012. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol. Cancer Ther. 11:909-920.
7. Halilovic E, Solit DB. 2008. Therapeutic strategies for inhibiting oncogenic BRAF signaling. Curr. Opin. Pharmacol. 8:419-426.
8. Infante JR, Fecher LA, Nallapareddy S, Gordon MS, Flaherty KT, Cox DS, DeMarini DJ, Morris SR, Burris HA, Messersmith WA. 2010. Safety and efficacy results from the first-in-human study of the oral MEK 1/2 inhibitor GSK1120212. J. Clin. Oncol. 28:2503.
9. Joseph EW, Pratilas CA, Poulikakos PI, Tadi M, Wang W, Taylor BS, Halilovic E, Persaud Y, Xing F, Viale A, Tsai J, Chapman PB, Bollag G, Solit DB, Rosen N. 2010. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc. Natl. Acad. Sci. U. S. A. 107:14903-14908.
10. Kefford R, Arkenau H, Brown MP, Millward M, Infante JR, Long GV, Ouellet D, Curtis M, Lebowitz PF, Falchook GS. 2010. Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. J. Clin. Oncol. 28:15s.
11. Poulikakos PI, Rosen N. 2011. Mutant BRAF melanomas-dependence and resistance. Cancer Cell 19:11-15.
12. Poulikakos PI, Solit DB. 2011. Resistance to MEK inhibitors: should we co-target upstream? Sci. Signal. 4:pe16. doi:10.1126/scisignal.2001948.
13. Ribas A, Flaherty KT. 2011. BRAF targeted therapy changes the treatment paradigm in melanoma. Nat. Rev. Clin. Oncol. 8:426-433.
14. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, Chodon T, Nelson SF, McArthur G, Sosman JA, Ribas A, Lo RS. 2010. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468:973-977.
15. Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P, Kehoe SM, Johannessen CM, Macconaill LE, Hahn WC, Meyerson M, Garraway LA. 2011. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J. Clin. Oncol. 29:3085-3096.
16. Whittaker S, Kirk R, Hayward R, Zambon A, Viros A, Cantarino N, Affolter A, Nourry A, Niculescu-Duvaz D, Springer C, Marais R. 2010. Gatekeeper mutations mediate resistance to BRAF-targeted therapies. Sci. Transl. Med. 2:35ra41. doi:10.1126/scitranslmed.3000758.
17. Cho K-j, Kasai RS, Park J-H, Chigurupati S, Heidorn SJ, van der Hoeven D, Plowman SJ, Kusumi A, Marais R, Hancock JF. 2012. Raf inhibitors target Ras spatiotemporal dynamics. Curr. Biol. 22:945-955.
18. Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, Ludlam MJ, Stokoe D, Gloor SL, Vigers G, Morales T, Aliagas I, Liu B, Sideris S, Hoeflich KP, Jaiswal BS, Seshagiri S, Koeppen H, Belvin M, Friedman LS, Malek S. 2010. RAF inhibitors prime wild-type RAF to activate theMAPKpathway and enhance growth. Nature 464:431-435.
19. Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, Hussain J, Reis-Filho JS, Springer CJ, Pritchard C, Marais R. 2010. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140:209-221.
20. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. 2010. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wildtype BRAF. Nature 464
21. Omerovic J, Laude AJ, Prior IA. 2007. Ras proteins: paradigms for compartmentalised and isoform-specific signalling. Cell. Mol. Life Sci. 64:2575-2589.
22. Apolloni A, Prior IA, Lindsay M, Parton RG, Hancock JF. 2000. H-ras but not K-ras traffics to the plasma membrane through the exocytic pathway. Mol. Cell. Biol. 20:2475-2487.
23. Choy E, Chiu VK, Silletti J, Feoktisitov M, Morimoto T, Michaelson D, Ivanov IE, Philips MR. 1999. Endomembrane trafficking of Ras: the CAAX motif targets proteins to the ER and Golgi. Cell 98:69-80.
24. Hancock JF, Paterson H, Marshall CJ. 1990. A polybasic domain or palmitoylation is required in addition to the CAAX motif to localize p21ras to the plasma membrane. Cell 63
25. Chandra A, Grecco HE, Pisupati V, Perera D, Cassidy L, Skoulidis F, Ismail SA, Hedberg C, Hanzal-Bayer M, Venkitaraman AR, Wittinghofer A, Bastiaens PI. 2012. The GDI-like solubilizing factor PDEdelta sustains the spatial organization and signalling of Ras family proteins. Nat. Cell Biol. 14:148-158.
26. Wang G, Deschenes RJ. 2006. Plasma membrane localization of Ras requires class C Vps proteins and functional mitochondria in Saccharomyces cerevisiae. Mol. Cell. Biol. 26:3243-3255.
27. Casey PJ, Solski PA, Der CJ, Buss JE. 1989. p21ras is modified by a farnesyl isoprenoid. Proc. Natl. Acad. Sci. U. S. A. 86:8323-8327.
28. Hancock JF, Magee AI, Childs JE, Marshall CJ. 1989. All ras proteins are polyisoprenylated but only some are palmitoylated. Cell 57:1167-1177.
29. Rowinsky EK. 2006. Lately, it occurs to me what a long, strange trip it's been for the farnesyltransferase inhibitors. J. Clin. Oncol. 24:2981-2984
30. Sebti SM, Der CJ. 2003. Searching for the elusive targets of farnesyltransferase inhibitors. Nat. Rev. Cancer 3:945-951.
31. Cox AD, Hisaka MM, Buss JE, Der CJ. 1992. Specific isoprenoid modification is required for function of normal, but not oncogenic, Ras protein. Mol. Cell. Biol. 12:2606-2615.
32. Hancock JF, Cadwallader K, Paterson H, Marshall CJ. 1991. A CAAX or a CAAL motif and a second signal are sufficient for plasma membrane targeting of ras proteins. EMBO J. 10:4033-4039.
33. Konstantinopoulos PA, Karamouzis MV, Papavassiliou AG. 2007. Posttranslational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Nat. Rev. Drug Discov. 6:541-555.
34. Hancock JF. 2003. Ras proteins: different signals from different locations. Nat. Rev. Mol. Cell Biol. 4:373-384.
35. Hancock JF, Parton RG. 2005. Ras plasma membrane signalling platforms. Biochem. J. 389:1-11.
36. Willumsen BM, Christensen A, Hubbert NL, Papageorge AG, Lowy DR. 1984. The p21 ras C-terminus is required for transformation and membrane association. Nature 310:583-586.
37. Prior IA, Harding A, Yan J, Sluimer J, Parton RG, Hancock JF. 2001. GTP-dependent segregation of H-ras from lipid rafts is required for biological activity. Nat. Cell Biol. 3:368-375.
38. Clarke S, Vogel JP, Deschenes RJ, Stock J. 1988. Posttranslational modification of the Ha-ras oncogene protein: evidence for a third class of protein carboxyl methyltransferases. Proc. Natl. Acad. Sci. U. S. A. 85: 4643-4647.
39. Gutierrez L, Magee AI, Marshall CJ, Hancock JF. 1989. Posttranslational processing of p21ras is two-step and involves carboxylmethylation and carboxy-terminal proteolysis. EMBO J. 8:1093-1098.
40. Hancock JF, Prior IA. 2005. Electron microscopic imaging of Ras signaling domains. Methods 37:165-172.
41. Prior IA, Muncke C, Parton RG, Hancock JF. 2003. Direct visualization of Ras proteins in spatially distinct cell surface microdomains. J. Cell Biol. 160:165-170.
42. Ripley BD. 1977. Modelling spatial patterns. J. R. Stat. Soc. B 39:172-192. 43. Diggle PJ, Mateu J, Clough HE. 2000. A comparison between parametric and non-parametric approaches to the analysis of replicated spatial point patterns. Adv. Appl. Probab. 32:331-343.
43. Diggle PJ, Mateu J, Clough HE. 2000. A comparison between parametric and non-parametric approaches to the analysis of replicated spatial point patterns. Adv. Appl. Probab. 32:331-343.
44. Plowman SJ, Muncke C, Parton RG, Hancock JF. 2005. H-ras, K-ras and inner plasma membrane raft proteins operate in nanoclusters that exhibit differential dependence on the actin cytoskeleton. Proc. Natl. Acad. Sci. U. S. A. 102:15500-15505.
45. Roy S, Lane A, Yan J, McPherson R, Hancock JF. 1997. Activity of plasma membrane-recruited Raf-1 is regulated by Ras via the Raf zinc finger. J. Biol. Chem. 272:20139-20145.
46. Grynkiewicz G, Poenie M, Tsien RY. 1985. A new generation of Ca2+ indicators with greatly improved fluorescence properties. J. Biol. Chem. 260:3440-3450.
47. Eisenberg S, Giehl K, Henis YI, Ehrlich M. 2008. Differential interference of chlorpromazine with the membrane interactions of oncogenic K-Ras and its effects on cell growth. J. Biol. Chem. 283:27279-27288.
48. Bayer R, Mannhold R. 1987. Fendiline: a review of its basic pharmacological and clinical properties. Pharmatherapeutica 5:103-136.
49. Huang C, Cheng J, Liu S, Chen I, Tsai J, Chou C, Tseng P, Jan C. 2009. Fendiline-evoked [Ca2+]i rises and non-Ca2+-triggered cell death in human oral cancer cells. Hum. Exp. Toxicol. 28:41-48.
50. Jan CR, Lee KC, Chou KJ, Cheng JS, Wang JL, Lo YK, Chang HT, Tang KY, Yu CC, Huang JK. 2001. Fendiline, an anti-anginal drug, increases intracellular Ca2+ in PC3 human prostate cancer cells. Cancer Chemother. Pharmacol. 48:37-41.
51. Lin MC, Jan CR. 2002. The anti-anginal drug fendiline elevates cytosolic Ca(2+) in rabbit corneal epithelial cells. Life Sci. 71:1071-1079.
52. Wang J, Cheng J, Chan R, Tseng L, Chou K, Tang K, Chung Lee K, Lo Y, Jan C. 2001. The anti-anginal drug fendiline increases intracellular Ca(2+) levels inMG63human osteosarcoma cells. Toxicol. Lett. 119:227-233.
53. Yeung T, Terebiznik M, Yu L, Silvius J, Abidi WM, Philips M, Levine T, Kapus A, Grinstein S. 2006. Receptor activation alters inner surface potential during phagocytosis. Science 313:347-351.
54. Bivona TG, Quatela SE, Bodemann BO, Ahearn IM, Soskis MJ, Mor A, Miura J, Wiener HH, Wright L, Saba SG, Yim D, Fein A, Perez de Castro I, Li C, Thompson CB, Cox AD, Philips MR. 2006. PKC regulates a farnesyl-electrostatic switch on K-Ras that promotes its association with Bcl-XL on mitochondria and induces apoptosis. Mol. Cell 21:481-493.
55. Navarro-Lerida I, Sanchez-Perales S, Calvo M, Rentero C, Zheng Y, Enrich C, Del Pozo MA. 2012. A palmitoylation switch mechanism regulates Rac1 function and membrane organization. EMBO J. 31:534-551.
56. Harding A, Hsu V, Kornfeld K, Hancock JF. 2003. Identification of residues and domains of Raf important for function in vivo and in vitro. J. Biol. Chem. 278:45519-45527.
57. Buick RN, Filmus J, Quaroni A. 1987. Activated H-ras transforms rat intestinal epithelial cells with expression of alpha-TGF. Exp. Cell Res. 170: 300-309.
58. Ciardiello F, Kim N, McGeady ML, Liscia DS, Saeki T, Bianco C, Salomon DS. 1991. Expression of transforming growth factor alpha (TGF alpha) in breast cancer. Ann. Oncol. 2:169-182.
59. Hamilton M, Wolfman A. 1998. Ha-Ras and N-ras regulate MAPK activity by distinct mechanisms in vivo. Oncogene 16:1417-1428.
60. Hamilton M, Wolfman A. 1998. Oncogenic Ha-Ras-dependent mitogenactivated protein kinase activity requires signaling through the epidermal growth factor receptor. J. Biol. Chem. 273:28155-28162.
61. Oldham SM, Clark GJ, Gangarosa LM, Coffey RJ, Jr, Der CJ. 1996. Activation of the Raf-1/MAP kinase cascade is not sufficient for Ras transformation of RIE-1 epithelial cells. Proc. Natl. Acad. Sci. U. S. A. 93:6924-6928.
62. Weyhenmeyer R, Fenzl E, Apecechea M, Rehm KD, Dyde CJ, Johnson KJ, Friedel R. 1987. Tolerance and pharmacokinetics of oral fendiline. Arzneimittelforschung 37:58-62.
63. Plowman SJ, Ariotti N, Goodall A, Parton RG, Hancock JF. 2008. Electrostatic interactions positively regulate K-Ras nanocluster formation and function. Mol. Cell. Biol. 28:4377-4385.
64. Elad G, Paz A, Haklai R, Marciano D, Cox A, Kloog Y. 1999. Targeting of K-Ras 4B by S-trans,trans-farnesyl thiosalicylic acid. Biochim. Biophys. Acta 1452:228-242.
65. Shalom-Feuerstein R, Plowman SJ, Rotblat B, Ariotti N, Tian T, Hancock JF, Kloog Y. 2008. K-ras nanoclustering is subverted by overexpression of the scaffold protein galectin-3. Cancer Res. 68:6608-6616.
66. Zhou Y, Cho KJ, Plowman SJ, Hancock JF. 2012. Nonsteroidal antiinflammatory drugs alter the spatiotemporal organization of ras proteins on the plasma membrane. J. Biol. Chem. 287:16586-16595.
67. Zhou Y, Plowman SJ, Lichtenberger LM, Hancock JF. 2010. The antiinflammatory drug indomethacin alters nanoclustering in synthetic and cell plasma membranes. J. Biol. Chem. 285:35188-35195.
68. Bhagatji P, Leventis R, Rich R, Lin CJ, Silvius JR. 2010. Multiple cellular proteins modulate the dynamics of K-ras association with the plasma membrane. Biophys. J. 99:3327-3335.
69. Jan CR, Yu CC, Huang JK. 2001. Dual effect of the antianginal drug fendiline on bladder female transitional carcinoma cells: mobilization of intracellular Ca2+ and induction of cell death. Pharmacology 62:218-223.
70. Wander SA, Hennessy BT, Slingerland JM. 2011. Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J. Clin. Invest. 121:1231-1241.
71. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Egia A, Sasaki AT, Thomas G, Kozma SC, Papa A, Nardella C, Cantley LC, Baselga J, Pandolfi PP. 2008. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J. Clin. Invest. 118:3065-3074.
72. Dlugosz AA, Cheng C, Williams EK, Darwiche N, Dempsey PJ, Mann B, Dunn AR, Coffey RJ, Jr, Yuspa SH. 1995. Autocrine transforming growth factor alpha is dispensible for v-rasHa-induced epidermal neopla sia: potential involvement of alternate epidermal growth factor receptor ligands. Cancer Res. 55:1883-1893.
73. Larsson-Backstrom C, Arrhenius E, Sagge K. 1985. Comparison of the calcium-antagonistic effects of terodiline, nifedipine and verapamil. Acta Pharmacol. Toxicol. (Copenh) 57:8-17.
74. Nawrath H, Klein G, Rupp J, Wegener JW, Shainberg A. 1998. Open state block by fendiline of L-type Ca++channels in ventricular myocytes from rat heart. J. Pharmacol. Exp. Ther. 285:546-552.
75. Opie LH. 1987. Calcium channel antagonists. I. Fundamental properties: mechanisms, classification, sites of action. Cardiovasc. Drugs Ther. 1:411-430.
76. Schreibmayer W, Tripathi O, Tritthart HA. 1992. Kinetic modulation of guinea-pig cardiac L-type calcium channels by fendiline and reversal of the effects of Bay K 8644. Br. J. Pharmacol. 106:151-156.
77. Thomas G, Gurung IS, Killeen MJ, Hakim P, Goddard CA, Mahaut- Smith MP, Colledge WH, Grace AA, Huang CL. 2007. Effects of L-type Ca2+ channel antagonism on ventricular arrhythmogenesis in murine hearts containing a modification in the Scn5a gene modelling human long QT syndrome 3. J. Physiol. 578:85-97.
78. Zahradnik I, Minarovic I, Zahradnikova A. 2008. Inhibition of the cardiac L-type calcium channel current by antidepressant drugs. J. Pharmacol. Exp. Ther. 324:977-984.